Related Experiment Videos
Summary
D-penicillamine treatment can cause serious marrow depression, leading to decreased white blood cells and platelets. Six of ten patients died, highlighting the drug's potential toxicity.
Area of Science:
- Hematology
- Pharmacology
- Toxicology
Background:
- D-penicillamine is a chelating agent used to treat various conditions.
- Marrow depression is a known potential side effect of certain medications.
- Understanding drug-induced toxicity is crucial for patient safety.
Purpose of the Study:
- To investigate the hematological effects of D-penicillamine.
- To report cases of marrow depression associated with D-penicillamine administration.
- To identify trends in blood counts during D-penicillamine therapy.
Main Methods:
- Retrospective review of 10 patient cases.
- Analysis of sequentially recorded blood counts.
- Clinical diagnosis of marrow depression.
Main Results:
- Nine out of 10 patients exhibited marrow depression.
- Six patients (60%) died during the study period.
- A downward trend in white blood cell and platelet counts was observed in most patients receiving D-penicillamine.
- One patient developed leucopenia and thrombocytopenia concurrently with streptococcal septicaemia.
Conclusions:
- D-penicillamine can induce significant bone marrow suppression.
- Close monitoring of blood counts is essential during D-penicillamine treatment.
- The drug's potential for severe hematological toxicity warrants careful consideration.